Aktie A2QF5K EUCRATES BIOMEDICAL ACQUISITION CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Eucrates Biomedical Acquisition Corp.

Aktien

A2QF5K

VGG3141W1068

EUCR

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Eucrates Biomedical Acquisition Corp.(NasdaqCM:EUCR) dropped from NASDAQ Composite Index
EUCRATES BIOMEDICAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
Eucrates Biomedical Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Eucrates Biomedical Acquisition Corp. Auditor Raises 'Going Concern' Doubt
Eucrates Biomedical Acquisition to Dissolve, Liquidate
Eucrates Biomedical Acquisition : Announces Liquidation - Form 8-K
EUCRATES BIOMEDICAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
Eucrates Biomedical Acquisition Corp. Announces Liquidation
Eucrates Biomedical Acquisition : New Financial Obligation - Form 8-K
EUCRATES BIOMEDICAL ACQUISITION CORP. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)
EUCRATES BIOMEDICAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Eucrates Biomedical Acquisition Corp. announced that it has received $0.096 million in funding from Eucrates Llc
EUCRATES BIOMEDICAL ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Eucrates Biomedical Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
EUCRATES BIOMEDICAL ACQUISITION CORP. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)
Eucrates Biomedical Acquisition Corp. announced that it has received $0.6 million in funding from Eucrates Llc
EUCRATES BIOMEDICAL ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure (form 8-K)
EUCRATES BIOMEDICAL ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Eucrates Biomedical Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
EUCRATES BIOMEDICAL ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QF5K Aktie
  4. Nachrichten Eucrates Biomedical Acquisition Corp.
  5. Andere Sprachen